The biotech reported data from KOASTAL-1, the first of three phase 3 trials of navacaprant in major depressive disorder.

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Novartis has reported positive topline outcomes from the Phase III STEER trial of an investigational gene therapy, ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

If Altimmune can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Click ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Bristol Myers (BMY) Squibb announced results from POETYK PsA-1 and POETYK PsA-2, the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis.

PainReform ( (PRFX) ) has provided an update. PainReform announced that its Phase 3 clinical trial for PRF-110 did not meet ...

Bristol Myers Squibb (BMS) has announced positive topline results from two Phase III trials evaluating the efficacy and ...

PolyPid ( ) just unveiled an update. PolyPid announced that its Phase 3 SHIELD II trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgeri ...